Yen L, Davis K, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticulitis: results from a retrospective claims database analysis. Am J Gastroenterol. 2010 Oct 1;105(Suppl. 1):S431.
Carson R, Williams V, Nelson L, MacDougall J, Johnston J. Psychometric evaluation of patient-reported outcome measures for assessing IBS-c symptom severity and global change: results from a phase 2b study of linaclotide. Am J Gastroenterol. 2009 Oct 1;104:1113.
Mangel AW, Fehnel SE. Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am J Gastroenterol. 2006 Dec;101(12):2884-5.
Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:1-9.
Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Most bothersome symptoms in irritable bowel syndrome (IBS) patients. Am J Gastroenterol. 2004;99(10):842.
Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Correlating global outcome measures in Irritable Bowel Syndrome (IBS). Am J Gastroenterol. 2004;99(10):843.
Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001 Mar;96(3):803-11.
Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.
Mangel AW, Northcutt AR, Kong S, McSorley DJ. Validation of adequate relief as an endpoint in irritable bowel syndrome. Am J Gastroenterol. 1999;116:G4500.
Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P. Epidemiology of peptic ulcer disease in cirrhotic patients: role of helicobacter pylori infection. Am J Gastroenterol. 1998 Dec;93(12):2501-7.
Vakil N, McSorley DJ, Hahn BA. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.
Ciociola AA, McSorley DJ. Consistent criteria should be employed in calculating h. pylori (HP) eradication rates: application of different published study criteria to ranitidine bismuth citrate (RBC) clinical trial data. Am J Gastroenterol. 1996;91(9):1907.
Graham DY, Hirshowitz B, Ciociola AA, Sykes DL, McSorley DJ. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease. Am J Gastroenterol. 1995;90(9):638.
Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.
Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.
Euler AR, Johnson JA, Dawson D, Kleoudis C, McSorley DJ. A comparison of ranitidine 150mg and placebo administered at bedtime for maintenance of recurrent benign gastric ulcers. Am J Gastroenterol. 1992;87(9):1267.